Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 5/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 1.00 |
| ▸ | RET | P07949 | 10/20 | 0.77 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.76 |
| ▸ | FLT3 | P36888 | 4/20 | 0.73 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.73 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.72 |
| ▸ | CSF1R | P07333 | 2/20 | 0.70 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.70 |
| ▸ | SRC | P12931 | 2/20 | 0.70 |
| ▸ | FLT1 | P17948 | 2/20 | 0.70 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | FLT4 | P35916 | 2/20 | 0.70 |
| ▸ | ABL1 | P00519 | 2/20 | 0.70 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | GMNN | O75496 | 1/20 | 0.70 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5478517 | 1.00 | PDPK1 (1.00) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL17480337 | 0.90 | KDR (0.80) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL13081086 | 0.87 | RET (1.00) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL5475962 | 0.84 | PDGFRB (0.81) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL29394706 | 0.84 | RET (1.00) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL31726696 | 0.84 | RET (0.76) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL5475963 | 0.84 | PDGFRB (0.81) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL19979 | 0.84 | RET (1.00) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL19978 | 0.84 | RET (1.00) | PDPK1KDRRETPDGFRBFLT3 | |
| SCHEMBL4416658 | 0.84 | RET (1.00) | PDPK1KDRRETPDGFRBFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | claimed |
| EP-1259234-B9 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2007-02-14 | — | — | EP | claimed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | claimed |
| EP-1259234-B1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2006-08-16 | — | — | EP | claimed |
| EP-1680401-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Schering Aktiengesellschaft (DE) | 2006-07-19 | — | — | EP | claimed |
| WO-2005058309-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | LEO PHARMA A/S (DK) | 2005-06-30 | — | — | WO | claimed |
| WO-2005040116-A2 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-05-06 | — | — | WO | claimed |
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-04-28 | — | — | US | claimed |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | SUGEN INC. | 2003-10-09 | — | — | US | claimed |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. | 2003-04-17 | — | — | US | claimed |
| EP-1259234-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | claimed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | claimed |
| US-20070167488-A1 | Novel therapeutic use | LEO PHARMA A/S (DK) | 2007-07-19 | — | — | US | disclosed |
| EP-1259234-B9 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7105563-B2 | Indolinone derivatives and their use in treating disease-states such as cancer | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| EP-1696906-A1 | NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES | Leo Pharma A/S (DK) | 2006-09-06 | — | — | EP | disclosed |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | SUGEN INC. | 2003-10-09 | — | — | US | disclosed |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1259234-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | Sugen, Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001049287-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | SUGEN, INC. (US) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090541-A1 | Indolinone derivatives and their use in treating disease-states such as cancer | PDK3, PDK2, PDK4 | PDPK1 4/4885KDR 2521/4885RET 1754/4885 |
| US-20070167488-A1 | Novel therapeutic use | MAG, PMP22, MYT1 | PDPK1 1635/4885KDR 4334/4885RET 3720/4885 |
| US-20030073837-A1 | 3-HETEROARYLIDENYL-2-INDOLINONE COMPOUNDS FOR MODULATING PROTEIN KINASE ACTIVITY AND FOR USE IN CANCER CHEMOTHERAPY | DCK, TNK2, MKNK1 | PDPK1 4/4885KDR 2091/4885RET 882/4885 |
| US-20030191162-A1 | 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy | DCK, TNK2, MKNK1 | PDPK1 4/4885KDR 2091/4885RET 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.